AcquisitionsApr 6, 2026, 11:54 AM
Neurocrine Biosciences to Acquire Soleno Therapeutics for $53 per Share in Cash
AI Summary
Soleno Therapeutics has entered into a definitive agreement to be acquired by Neurocrine Biosciences for $53 per share in cash. The acquisition will occur via a tender offer followed by a merger, making Soleno a wholly-owned subsidiary of Neurocrine. This represents a significant event for Soleno shareholders, offering a defined exit price.
Key Highlights
- Neurocrine Biosciences will acquire all outstanding shares of Soleno Therapeutics for $53 per share in cash.
- The acquisition will proceed through a cash tender offer followed by a merger.
- The offer is subject to customary closing conditions, including the tender of a majority of Soleno's outstanding shares and regulatory approvals.